FLUXID
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Sep 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FLUXID by UCB Pharma is clinical pharmacology in adults gi effects famotidine is a competitive inhibitor of histamine h 2 -receptors. First approved in 2004.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUXID is an oral, orally disintegrating tablet formulation of famotidine, an H2-receptor antagonist that competitively inhibits gastric acid secretion. It is indicated for the treatment of duodenal ulcers and related acid-peptic disorders by suppressing both basal and stimulated gastric acid production. The drug achieves 86-94% inhibition of nocturnal gastric acid secretion with a 10-12 hour duration of action.
LOE Approaching
FLUXID is approaching loss of exclusivity in a mature GI acid-suppression market with moderate competitive pressure; brand team size likely declining as generic competition intensifies.
Mechanism of Action
CLINICAL PHARMACOLOGY IN ADULTS GI Effects Famotidine is a competitive inhibitor of histamine H 2 -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by…
Worked on FLUXID at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.